A 14-year-old girl with leukemia had Doppler ultrasound evidence of hepatic necrosis, thought to be caused by a lipid formulation of amphotericin B, which has not been previously reported. It seems prudent to exert caution when retreating patients with previous hepatocellular damage with lipid formulations of amphotericin B.
agents that she had been given for Escherichia coli bacteremia, but she was given no AmBisome. However, results of liver function tests done at the time of admission (day 43) were normal and remained normal throughout this hospital admission, with the exception of a mild elevation in the alkaline phosphatase (ALKP) level.
On day 85, she was readmitted to undergo second consolidation chemotherapy with ICE, and she received the same prophylactic antibiotics. At the time of this admission, however, the g-GT and ALKP levels were noted to be marginally elevated. There was a further slight progressive rise in these 2 enzyme level from day 85 to day 101, during which time she again received ICE, prophylactic antimicrobial agents, and piperacillin-tazobactam for neutropenic fever. Between days 101-111, AmBisome, 200 mg/day, was administered for ARNF. During this time the g-GT and ALKP levels rose sharply. On day 114, she was discharged while in complete hematologic remission and afebrile. Results of all cultures were negative for pathogens, and there was no clinical or radiological evidence of invasive fungal infection.
On day 133, she was readmitted with severe jaundice with right upper-quadrant pain and fullness. Liver enzyme levels, including the aspartate aminotransferase (AST), ALT, and bilirubin levels, had risen substantially further after discontinuation of the AmBisome, a finding consistent with a predominant obstructive presentation. Results of serological testing for viral hepatitis types A, B, and C, and Epstein-Barr virus were negative. Results of tests for antinuclear, antimitochondrial, antismooth muscle antibodies were negative. Abdominal ultrasound examination indicated sedimentation, gallbladder sludge, and biliary tree dilatation. An intraluminary soft-tissue mass was present in the dilated (13-mm) common bile duct, as confirmed by contrast CT. The results of endoscopic retrograde cholangiopancreatography performed a few days later were normal. A further Doppler ultrasound examination confirmed decompression of the biliary obstruction. However, there was a substantial hypoechoic defect in the liver tissue, the epicenter of which was located in segments 3 and 4 of the left hepatic lobe (figure 1). The hemodynamic parameters in the acute and follow-up (36-h) phases, respectively, were as follows: hepatic artery maximum velocity, 134 cm/s and 48 cm/s; portal vein maximum velocity, 47 cm/s and 16 cm/s; and hepatic artery resistivity index, 0.58 and 0.60. Over the course of the next 36 days, the liver function abnormalities spontaneously improved, and the imaging pathologies and hemodynamic Doppler data normalized entirely. 
NOTE. ALKP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BILI, bilirubin; COT, consolidation therapy; g-GT, g-glutamyl transferase; and ICE, idarubicin/cytarabine/etoposide; P-T, piperacillin-tazobactam.
See table 1 for an overview of laboratory values obtained on specific treatment days.
Discussion. We postulate that AmBisome had contributed to or directly caused serious liver damage in our patient. There was no elevation of liver enzyme levels while the patient was receiving ICE, ciprofloxacin, fluconazole and piperacillin-tazobactam, but initial cholestatic damage occurred immediately after AmBisome administration, with this resolving after discontinuation of AmBisome therapy. Reintroduction of chemotherapy and systemic antibiotic therapy during first consolidation therapy had no effect on the liver enzymes, making their role unlikely (ICE and fluconazole were subsequently reintroduced on day 250ϩ, with no elevation of liver enzyme levels to confirm this view).
At the start of the second consolidation therapy (day 85), there was a slight elevation in g-GT and ALKP levels, which, in the absence of administration of medications between days 64 and 85, is inexplicable but which suggests a background of mild cholestatic liver disease. The reason for their slow, progressive rise before and during further ICE, piperacillin-tazobactam, ciprofloxacin, and fluconazole therapy is likewise unclear. However, mild disturbances that occur without a precise cause in liver enzyme levels are a common phenomenon in this group of patients. Furthermore, the persistent, slight elevation of the ALKP throughout the total period of the patient's illness and at times when the g-GT level was normal suggests that bone growth may have been responsible. Hepatosplenic candidiasis is another possibility, but it is unlikely in the absence of fever, negative results of cultures, focal hepatosplenic lesions on imaging, subsequent normalization of liver enzyme levels, and fluconazole administration. The subsequent reintroduction of AmBisome was associated with a sharp and severe elevation of liver enzyme levels, which suggests that AmBisome was an important factor.
Of interest is the progressive, substantial deterioration in the results of liver function tests during the 3 weeks after completion of AmBisome treatment. The radiological imaging series is suggestive of focal hepatic necrosis with an accompanying cholangitis-hepatitis type of flow hemodynamics, as assessed by Doppler ultrasonography [1] . One explanation for the sludge and sedimentation (which causes biliary tree obstruction that simulates an intraluminary mass lesion), is massive desquamation of inflammatory cells and necrotic liver-tissue shedding.
The findings on radiological imaging were paralleled by the cholestatic profile of the liver enzymes, which, when viewed together, gradually evolved into a frank picture of obstruction with secondary hepatocellular damage at approximately day 133.
Patients such as ours receive multiple drugs and are at risk from other factors (e.g., sepsis), many of which are potentially hepatotoxic. It is, therefore, difficult to be certain as to precisely which agent caused the liver damage. Rechallenge with ICE, fluconazole, ciprofloxacin, and piperacillin-tazobactam therapy was unassociated with an increase in liver enzyme levels, and this makes a direct role for these agents unlikely. On the other hand, a close temporal association of an increase in liver enzyme levels and AmBisome administration on 2 separate occasions suggests that this agent was at least a contributory factor to the liver damage.
Lipid formulations of amphotericin B are important antifungal agents with a therapeutic index that is superior to that of conventional amphotericin B. Less than 5% of patients experience adverse reactions. A mild degree of liver dysfunction that occurs in association with AmBisome therapy is common [2] . Serum glutamic oxaloacetic transaminase (SGOT) and ALKP levels rise from normal baseline values in 28% and 37% of patients, respectively. Concomitant administration of other hepatotoxic drugs to ill patients makes it difficult to ascribe a causal role to lipid formulations of amphotericin B.
Severe liver damage caused by AmBisome has not, to our knowledge, been reported in humans, although 1 case caused by conventional amphotericin B has been reported [3] . Two additional cases of fulminant fatal hepatic failure, one of which involved a high dosage of AmBisome (10 mg/kg/day), have been identified, but a clear role for AmBisome could not be determined [4] . In our case report, however, the rechallenge phenomenon is strongly suggestive of a role for AmBisome. Extremely high multiple dosages of AmBisome (50 and 75 mg/ kg/day), when given to healthy rodents, rapidly produce high levels of SGOT (median value, 5035 IU/L and 8660 IU/L, for the 2 doses, respectively), which have been associated with a mortality rate of 50%-90% [5] .
It appears that the overall rate of hepatotoxicity is no greater for AmBisome than for conventional amphotericin B [6] . Fulminant hepatitis appears to be an exceedingly rare occurrence with the use of either drug. It is possible that some minor liver damage had been caused by one of the chemotherapeutic agents prior to the second course of AmBisome and had predisposed the patient to subsequent severe liver damage. It is not known whether the AmBisome rechallenge in our patient, who had previous hepatoxicity, had placed that patient at high risk for subsequent severe liver damage. This would be likely if the mechanism for the toxicity was mediated by serum antibodies directed against the AmBisome. Indeed a polyclonal antibody response to amphotericin B occurs in experimental animals, and such antibodies have previously been utilized to develop an ELISA for estimation of the serum amphotericin B concentration [7] . Therefore, it should be possible to directly measure and classify the putative Ig response to amphotericin B in our patient. It is possible that the lipid component of AmBisome may initiate some immunologic reactions, as has been discussed elsewhere [8] . The development of a specific ELISA may therefore be useful for confirmation of the role of AmBisome in such patients and delineation of the type of interactions between AmBisome and the immune system. Although findings of abnormal results of liver function tests caused by AmBisome therapy are inconsequential in most patients, we would urge caution in reexposing patients with documented prior hepatotoxicity associated with AmBisome therapy to further treatment with this drug or other amphotericin B preparations.
